Common cough medicine could slow dementia in Parkinson's patients, study hints
Nearly half of those diagnosed with Parkinson's develop dementia within 10 years, with progressively worsening memory loss, confusion, hallucinations, and mood changes, which affect patients, families, and the healthcare system.
'Current therapies for Parkinson's disease and dementia address symptoms but do not stop the underlying disease,' said neurologist Stephen Pasternak from Western University in Canada.
Now, a new year-long clinical trial suggests that the cough medicine Ambroxol – used safely for decades in Europe – can potentially slow the development of these symptoms.
The small scale study, published in the journal JAMA Neurology, monitored 55 participants with Parkinson's dementia, assessing their memory, psychiatric symptoms, and the blood marker GFAP linked to brain damage.
One group of participants received Ambroxol daily while the other received a placebo.
Researchers found that the drug was safe, well-tolerated and reached therapeutic levels in the brain.
While psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol, scientists said in a statement.
'Individuals receiving placebo showed a clinically meaningful worsening in neuropsychiatric symptoms, whereas those receiving ambroxol remained stable,' researchers wrote in the study.
Those with high risk variants of a key gene linked to dementia showed improved cognitive performance on Ambroxol, they said.
GFAP levels increased in the placebo group, but stayed stable with Ambroxol, suggesting that the cough medicine may have the potential to protect the brain from faster deterioration under Parkinson's.
'Ambroxol was safe, well-tolerated, and demonstrated target engagement,' scientists wrote, however adding that the drug's clinical effect on cognition was 'not confirmed' in the study.
Previous studies have shown that Ambroxol supports a key enzyme called glucocerebrosidase (GCase), whose levels are low in Parkinson's patients.
Researchers previously found that Ambroxol could help treat the rare genetic disorder Gaucher disease in children, which is caused by a deficiency of GCase.
When this enzyme doesn't work properly, waste can build up in brain cells, leading to damage.
'These findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist,' Dr Pasternak said.
'If a drug like Ambroxol can help, it could offer real hope and improve lives,' he said.
While the cough medicine is approved in Europe for treating respiratory conditions, with a long-standing safety record, including use at high doses and during pregnancy, it is not approved for any use in the US or Canada.
Scientists hope the pharmacological data from this study could help conduct larger clinical trials to test the effectiveness of Ambroxol in slowing dementia symptoms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
5 minutes ago
- The Independent
More people are being admitted to hospital for devastating reason
NHS emergency departments are experiencing unprecedented levels of admissions due to hunger, researchers claim. Admissions to Accident and Emergency units for lack of food have more than tripled, rising by nearly 219 per cent in England over five years. This surge, from 70 patients in 2018-19 to 230 in 2023-24, is attributed to the cost-of-living crisis, spiralling food prices, and increased poverty. Experts warn that the significant rise reflects growing food insecurity, with the Resolution Foundation predicting a bleak outlook for UK living standards. While hunger-related admissions saw the fastest proportionate rise, the biggest actual increase in A&E numbers was due to adverse reactions to standard medical procedures.
Telegraph
6 minutes ago
- Telegraph
Mounjaro is almost tripling in price – here's what it means for you
Its amazing results have been hailed by Jeremy Clarkson, Whoopi Goldberg and The Telegraph 's own Allison Pearson, but from next month, the popular weight-loss drug Mounjaro could become inaccessible to many people across the UK. The wholesale price of the medication is set to shoot up by 170 per cent from September 1, with the highest dose (15mg) increasing from £122 per month to £330. Mounjaro (also known as tirzepatide) is an injectable drug made from a synthetic 'analogue' of the two molecules GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). These hormones, which are also produced naturally in the brain, regulate appetite and insulin production. 'The main effect of the hormones in Mounjaro is to tell you that you are 'full',' says Prof Ketan Dhatariya, a consultant in diabetes, endocrinology and general medicine at Norfolk and Norwich University Hospital. 'Imagine you've been invited to a friend's house for dinner, and the food isn't ready yet, so you fill up on Twiglets and Pringles. But when the meal is served, you are no longer hungry and you can't eat a thing.' Patients can get the medication through an NHS prescription, or more commonly from a private provider such as Boots, MedExpress or Pharmacy2U. Why is the price increasing? American pharmaceutical companies have faced pressure from Donald Trump to make drugs more affordable by offsetting higher prices to other countries, including the UK. Until now, UK providers have paid significantly lower wholesale prices than other European countries, meaning patients have been able to pay a reduced monthly fee. What will the price change be and when will it come into effect? Pharmacies in the UK currently pay between £92 and £122 for the drug, depending on the price. From September 1, a 2.5mg dose will cost £133, and the higher doses, 12.5mg and 15mg, will cost £330. Some companies, such as Pharmacy2U, have confirmed that their retail prices will freeze for the foreseeable future. Boots has confirmed that its prices will change but that it will do its best to keep them fair and accessible. Why do costs vary? Costs will vary depending on the provider and the dose. There are six strengths of Mounjaro: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. The higher the dose, the more expensive the monthly cost. How do the price rises in the UK compare with Europe and the United States? In the UK, the highest dose of Mounjaro currently costs £122. In the US, the same dose costs roughly $1,000 (£743) without insurance. Inish Pharmacy, Ireland's leading online pharmacy, charges €289 (£250) for 2.5mg of Mounjaro and the higher doses of 7.5mg and 10mg cost €465 (£402). In Spain, patients can expect to pay an average of €271 (£235) per month and in France, a 5mg dose costs around €250 (£217). Eli Lilly, the US manufacturer of Mounjaro, originally set lower prices in the UK to avoid long supply delays, ease waiting-list pressures and compete with other GLP-1 medications. I'm on Mounjaro. What should I do next? It will depend on how you get your medication. If you get your prescription through the NHS, you are likely to be unaffected. Eli Lilly has agreed a separate supply arrangement with the NHS, which ensures that prices will remain stable. If you receive your medication through a private provider, you could speak with it directly to see whether it is offering discounts. Alternatively, you could switch to a provider with lower costs, such as Pharmacy2U. If you're thinking about switching to a cheaper medication entirely, Wegovy and Rybelsus are also available in the UK, as well as Ozempic – a type 2 diabetes medication that is prescribed off-label for weight loss. How can I get Mounjaro for free? The NHS offers Mounjaro for those who need it as part of their primary care. In order to qualify, you would need to have a body mass index (BMI) of 40 (or 37.5 for ethnic minorities) or above, and at least four weight-linked health conditions such as: Type 2 diabetes High blood pressure Heart disease Abnormal cholesterol or blood fats Obstructive sleep apnoea (a sleep-related breathing problem) In June 2026, it will expand to include people with a BMI of 35 to 39.9 who have four of the conditions listed above. In April 2027, it will also be offered to people with a BMI of 40 and above who have just three out of the five conditions. How can I find a reputable provider? The recent update has caused concern among some GPs that patients unable to afford the new prices may turn to the black market for the drug out of desperation. Patients should ensure that any potential Mounjaro provider is registered with the General Pharmaceutical Council or the Care Quality Commission. They can also check customer satisfaction through sites such as Trustpilot. Pharmacies attached to high-street companies such as Boots, Asda, Lloyds Pharmacy and Superdrug can typically be trusted. What are some of the alternatives to Mounjaro? Ozempic In the UK, Ozempic is licensed only as a type 2 diabetes treatment. It is possible to find a private doctor who is willing to prescribe Ozempic for weight loss outside of licensed conditions, but NHS doctors cannot. Because of this, it is recommended that patients use Wegovy instead, as it uses the same active ingredient (semaglutide). Private providers may charge between £150 and £180 for the lowest dose (0.25mg) to £165-£180 for the highest dose (1mg). Wegovy Wegovy is a version of Ozempic that can be prescribed for weight loss. The dosing of Wegovy is more clinically suitable for weight loss and ranges between £118.98 for the lowest dose (0.25mg) and £188.98 for the highest (2.4mg). It is seen as a safer, more effective option than Ozempic. Rybelsus Rybelsus is a tablet GLP-1 medication used to treat type 2 diabetes. Like Ozempic, it is not licensed for weight loss but it also contains semaglutide and can sometimes be prescribed 'off-label'. Rybelsus can be prescribed for free by the NHS, or off-label prescriptions can be purchased from private doctors and pharmacies for between £150 and £400, depending on the number of tablets. Can I order multiple pens now so I don't have to buy them after the price rise? Reorders depend on the provider. Boots is allowing patients to purchase up to three pens in advance before September 1. Some pharmacies such as Lloyds Pharmacy are selling medication only to existing customers, and allowing only one reorder per patient. Can I stay on Mounjaro for ever? Yes, you can use Mounjaro in the long term, says Dr Kaywaan Khan, a GP and weight loss and wellbeing specialist at Hannah London. Some people 'will take the medication for ever because they not only have obesity as a chronic disease, but they [have conditions such as] heart disease or diabetes, so taking this medication is part of their core health treatment and preventative health care', Dr Khan adds. Can I switch from Mounjaro to Wegovy? You should not take Mounjaro and Wegovy at the same time. If you decide to switch, you should wait at least a week before taking the new medication. You should also increase your dose gradually.
The Independent
2 hours ago
- The Independent
Hunger-driven A&E admissions spiral amid cost-of-living crisis
Hungry patients are overwhelming NHS emergency departments at unprecedented levels, researchers claim. Admissions to hospital Accident and Emergency (A&E) units because of hunger have more than tripled, rising by nearly 219 per cent in five years, figures suggest. Analysis of NHS data shows a lack of food was the fastest growing cause of A&E admissions in England between 2018-19 and 2023-24, as food prices and poverty spiralled. As the cost-of-living crisis gripped the UK, experts repeatedly warned that households were being plunged into poverty, with food bank use soaring and charities finding parents going hungry so their children could eat. Health experts warned in 2022 that millions of people were facing a 'significant humanitarian crisis', exacerbated by rocketing fuel bills. In 2018-19, 70 patients needed emergency care for hunger, the statistics show, but the figure shot up to 230 after five years – a 218.5 per cent increase. Paula Lingard, of the ID Band Company, which analysed the NHS data, said: 'The significant rise in admissions related to lack of food is particularly concerning and may reflect growing food insecurity in England, highlighting the importance of addressing basic needs as part of our approach to public health.' Recently, the Resolution Foundation think tank said the outlook for living standards for UK households remains bleak for the rest of the 2020s, which it said could become 'the first decade of the modern era to witness no improvement in disposable incomes across Britain'. Household debts have continued to rise since last year. The biggest actual increase in A&E admission numbers over the five years was down to adverse reactions to standard medical procedures. Cases rose from 40,881 to 103,295 over the five years – a 144.9 per cent increase. Environmental pollution-related illnesses caused the second-biggest proportionate rise in admissions, increasing by 191 per cent in five years. Patient numbers tripled from 16 to 48. Surgical errors drove the third-highest percentage jump, with emergency figures rising 179.9 per cent. NHS records show 4,094 patients needed urgent treatment after medical mishaps in 2023-24, against 1,418 in 2018-19. Cardiovascular equipment problems more than doubled, from 325 to 775. But cases of self-harm fell, with deliberate drug overdoses dropping by nearly half between 2018 and 2024, from 12,298 to 6,499. Shotgun and rifle assault injuries dropped from 56 in 2018-19 to just 17. The Independent has approached the Department for Health and Social Care for comment.
